Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Recruiting
Observational Study
Osteoporosis
Osteoporosis, Steroid Induced
Inflammatory Rheumatism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 25 – 90
- Sex
- Any
- Study type
- Observational
- Participants needed
- 160 (estimated)
- Sponsor
- Diakonhjemmet Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at incre…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* diagnosis of inflammatory rheumatic joint disease
* indication of disease modifying treatment initiation with or without glucocorticoids OR
* stable DMARD treatment with parenteral glucocorticoid injection
Exclusion Criteria:
* known osteoporosis or osteoporosis treatment
* …
Contacts